Shenghui Xue

Shenghui Xue

Auto-generated profile, based on publicly available information

Shenghui Xue

Georgia State University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XLXia Liu
Xia Liu
OOObiamaka Obianyo
Obiamaka Obianyo
CCChi Bun Chan
Chi Bun Chan
JHJunjian Huang
Junjian Huang
SXShenghui Xue
Shenghui Xue
KYKeqiang Ye
Keqiang Ye
7,8-dihydroxyflavone (7,8-DHF), a newly identified small molecular TrkB receptor agonist, rapidly activates TrkB in both primary neurons and the rodent brain and mimics the physiological functions of the cognate ligand BDNF. Accumulating evidence supports that 7,8-DHF exerts neurotrophic effects in a TrkB-dependent manner. Nonetheless, the differences between 7,8-DHF and BDNF in activating TrkB remain incompletely understood. Here we show that 7,8-DHF and BDNF exhibit different TrkB activation kinetics in which TrkB maturation may be implicated. Employing two independent biophysical approaches, we confirm that 7,8-DHF interacts robustly with the TrkB extracellular domain, with a Kd of ∼10 nm. Although BDNF transiently activates TrkB, leading to receptor internalization and ubiquitination/degradation, in contrast, 7,8-DHF-triggered TrkB phosphorylation lasts for hours, and the internalized receptors are not degraded. Notably, primary neuronal maturation may be required for 7,8-DHF but not for BDNF to elicit the full spectrum of TrkB signaling cascades. Hence, 7,8-DHF interacts robustly with the TrkB receptor, and its agonistic effect may be mediated by neuronal development and maturation.

29 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMani Salarian
Mani Salarian
RTRavi Chakra Turaga
Ravi Chakra Turaga
SXShenghui Xue
Shenghui Xue
MNMaysam Nezafati
Maysam Nezafati
KHKhan Hekmatyar
Khan Hekmatyar
JYJenny Yang
Jenny Yang
Early diagnosis and noninvasive detection of liver fibrosis and its heterogeneity remain as major unmet medical needs for stopping further disease progression toward severe clinical consequences. Here we report a collagen type I targeting protein-based contrast agent (ProCA32.collagen1) with strong collagen I affinity. ProCA32.collagen1 possesses high relaxivities per particle (r1 and r2) at both 1.4 and 7.0 T, which enables the robust detection of early-stage (Ishak stage 3 of 6) liver fibrosis and nonalcoholic steatohepatitis (Ishak stage 1 of 6 or 1 A Mild) in animal models via dual contrast modes. ProCA32.collagen1 also demonstrates vasculature changes associated with intrahepatic angiogenesis and portal hypertension during late-stage fibrosis, and heterogeneity via serial molecular imaging. ProCA32.collagen1 mitigates metal toxicity due to lower dosage and strong resistance to transmetallation and unprecedented metal selectivity for Gd3+ over physiological metal ions with strong translational potential in facilitating effective treatment to halt further chronic liver disease progression.

26 November 2012 in Metallomics
Verified
Journal Article
Closed access
PDF file
YZYubin Zhou
Yubin Zhou
SXShenghui Xue
Shenghui Xue
JYJenny Yang
Jenny Yang
Calcium ion (Ca2+), the fifth most common chemical element in the earth's crust, represents the most abundant mineral in the human body. By binding to a myriad of proteins distributed in different cellular organelles, Ca2+ impacts nearly every aspect of cellular life. In prokaryotes, Ca2+ plays an important role in bacterial movement, chemotaxis, survival reactions and sporulation. In eukaryotes, Ca2+ has been chosen through evolution to function as a universal and versatile intracellular signal. Viruses, as obligate intracellular parasites, also develop smart strategies to manipulate the host Ca2+ signaling machinery to benefit their own life cycles. This review focuses on recent advances in applying both bioinformatic and experimental approaches to predict and validate Ca2+-binding proteins and their interactomes in biological systems on a genome-wide scale (termed “calciomics”). Calmodulin is used as an example of Ca2+-binding protein (CaBP) to demonstrate the role of CaBPs on the regulation of biological functions. This review is anticipated to rekindle interest in investigating Ca2+-binding proteins and Ca2+-modulated functions at the systems level in the post-genomic era.

13 May 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SXShenghui Xue
Shenghui Xue
HYHua Yang
Hua Yang
JQJingjuan Qiao
Jingjuan Qiao
FPFan Pu
Fan Pu
JJJie Jiang
Jie Jiang
JYJenny Yang
Jenny Yang
Significance: Primary and metastatic liver cancers that are associated with high mortality rates and poor treatment responses are only diagnosed at late stages, due to the lack of highly sensitive contrast agents and robust imaging methodologies. We have developed a protein MRI contrast agent (ProCA32) by engineering high-affinity Gd 3+ -binding pockets in rat and human α-parvalbumin. ProCA32 can function as both a T 1 - and T 2 -weighted contrast agent, which enables noninvasive detection of early-stage micrometastatic liver tumors with sizes as small as 0.24 mm using T 1 - and T 2 -weighted or T 2 /T 1 ratio MRI. Our protein-based MRI contrast agents and imaging methodology are expected to provide robust results for the early detection of liver cancer as well as other liver diseases.

13 March 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
GQGuifen Qiang
Guifen Qiang
SXShenghui Xue
Shenghui Xue
JYJenny J. Yang
Jenny J. Yang
GDGuanhua Du
Guanhua Du
XPXiaobin Pang
Xiaobin Pang
KYKeqiang Ye
Keqiang Ye
Insulin replacement therapy is a widely adopted treatment for all patients with type 1 diabetes and some with type 2 diabetes. However, injection of insulin has suffered from problems such as tissue irritation, abscesses, discomfort, and inconvenience. The use of orally bioactive insulin mimetics thus represents an ideal treatment alternative. Here we show that a chaetochromin derivative (4548-G05) acts as a new nonpeptidyl insulin mimetic. 4548-G05 selectively activates an insulin receptor (IR) but not insulin-like growth factor receptor-I or other receptor tyrosine kinases. Through binding to the extracellular domain of the IR, 4548-G05 induces activation of the receptor and initiates the downstream Akt and extracellular signal–related kinase pathways to trigger glucose uptake in C2C12 myotubes. Moreover, it displays a potent blood glucose-lowering effect when administrated orally in normal, type 1 diabetic, and type 2 diabetic mice models. Therefore, 4548-G05 may represent a novel pharmacological agent for antidiabetes drug development.

17 January 2013 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
SXShenghui Xue
Shenghui Xue
JQJingjuan Qiao
Jingjuan Qiao
FPFan Pu
Fan Pu
MCMathew Cameron
Mathew Cameron
JYJenny Yang
Jenny Yang